 A two-arm, Phase 23 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavirritonavir DRVr in HIV-1 infected, virologically suppressed paediatric participants. 